How is GLP-1 pricing evolving as the market saturates? A healthcare consultant breaks down MFN pricing pressure, the impact of transparency rules on compounders, Novo Nordisk’s $199 offer, and how oral GLP-1s and potential Part D pilots could shape long-term pricing: https://bit.ly/44HRVXQ
Guidepoint
Information Services
New York, NY 191,941 followers
The Experts at Finding Expertise
About us
Guidepoint is a research enablement platform designed to advance understanding and empower our clients’ decision-making process. Powered by innovative technology, real-time data, and hard-to-source expertise, we enable our clients to turn answers into action. Backed by a network of nearly 1.75 million experts, and Guidepoint’s 1,600 employees worldwide we inform leading organizations’ research by delivering on-demand intelligence and research on request. With Guidepoint, companies and investors can better navigate the abundance of information available today, making it both more useful and more powerful. For more information, visit www.guidepoint.com.
- Website
-
http://www.guidepoint.com
External link for Guidepoint
- Industry
- Information Services
- Company size
- 1,001-5,000 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2003
- Specialties
- Market Research, Phone Consultations, Surveys, Group Meetings and Events, Custom Research Reports, Healthcare, Consumer Goods & Services, Tech, Media & Telecom, Energy, Industrials & Materials, Financial & Business Services, Legal & Regulatory, and Experts
Locations
Employees at Guidepoint
Updates
-
Is Valve’s new Steam hardware positioned to reshape the gaming ecosystem? An engineer from Wizcorp Inc. discusses how the Steam Machine’s specs stack up for the average gamer, the challenges to becoming a default home console, and whether Valve’s multi-hardware strategy sets it up for success: https://bit.ly/4ov5GQF
-
-
How is Apple Pay Later evolving inside Apple’s ecosystem? A Senior Advisor in Global Payments explains Pay Later’s role as an engagement tool, how Apple uses first-party data for capital-efficient underwriting, and why monetization may come more from ecosystem trust than BNPL margins: https://bit.ly/3XoaoVw
-
-
We’re pulling back the curtain on Alpha — the tool built to give investors visibility into company performance long before earnings season. In a market where even small shifts in procedure volume, channel behavior, or competitor momentum can impact performance, Alpha delivers a level of visibility that traditional models simply can’t match. And the results speak for themselves: 0.83% weighted mean absolute percentage error With sub-1% error, Alpha provides precision forecasting across key MedTech names, grounded in real-time sales intelligence and proprietary signal tracking. 80% directional accuracy versus consensus Alpha correctly projects beats, misses, and in-line quarters with remarkable consistency, helping investors position ahead of the market. Why does this matter? At Qsight, we built Alpha to turn fragmented industry signals into higher conviction and earlier insights. Data that closes the gap between what’s happening in the field and what’s reflected on the street. If you’re an investor, analyst, or strategic leader navigating the MedTech landscape, Alpha is built to give you clarity where others see noise. 🔗 Reach out to learn more about Alpha and how Qsight is redefining forward looking intelligence in medtech. https://lnkd.in/dzW_4JH9
-
-
Is 2026 the ramp year for humanoid robots? A Principal Control Engineer at a leading humanoid robotics company assesses when commercial bipedal robots will scale, how Tesla’s Optimus compares to other OEMs, and whether AI, hand tech, and pricing are ready for real industrial deployment: https://bit.ly/48ljw3D
-
-
The aesthetics market is at an inflection point. As highlighted in this week’s The Business of Fashion, HA filler demand has flattened after years of rapid growth, driven by shifting consumer sentiment, economic pressure, and a move toward more natural results. Guidepoint Qsight’s real-time injectables data, cited in the article, confirms this reset and helps manufacturers and providers understand the drivers behind it. The winners in 2025–26 will be those who adapt quickly: reframing category messaging, anticipating patient preferences, and building strategies grounded in data rather than assumptions. If you’re rethinking your growth playbook, we’re here to help. Click here to read more from the article: Inside the Playbook to Revive Filler Sales | BoF https://lnkd.in/ep5RqZrC
-
How might the DOJ probe and tariff shifts reshape U.S. cattle pricing? The CEO of R-CALF USA discusses how packer contracting influences rancher prices, whether country-of-origin labeling could boost domestic production, and what tightening supply means for live cattle and beef pricing heading into 2026: https://bit.ly/3XEp3vL
-
-
How differentiated is Sensi AI’s audio-only monitoring in home care? A Former Sensi AI marketing leader discusses the system’s accuracy, competitive edge versus video and wearables, current market penetration, and the ROI agencies are seeing: https://bit.ly/4o5Q4Tw
-
-
In fast-moving markets, insight is everything. Guidepoint connects you with experts who understand the nuances of their industries. Our network delivers guidance that helps decisions stay on track. Here are three experts we sourced just last week. Connect with an expert today: https://lnkd.in/eVyGn43S
-